MTVA News & Events

MetaVia announced a strong global intellectual property portfolio supporting lead asset DA-1726, a novel, dual oxyntomodulin, or OXM, analog agonist that functions as a glucagon-like peptide-1 receptor, or GLP1R, and glucagon receptor, or GCGR, for the treatment of obesity and related metabolic disorders. This currently includes 39 granted and pending patents in the U.S. and internationally, providing protection into 2041, unless extended further. MetaVia's patent portfolio, exclusively licensed from Dong-A ST provides broad protection covering the novel peptide structure of DA-1726 as well as its design as a long-acting dual-incretin therapy. Together, these protect both the core molecule and its therapeutic use in obesity, metabolic disease, and associated cardiometabolic conditions, strengthening the company's long-term development and commercialization position in one of the fastest-growing areas of medicine. DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP1R/GCGR dual agonist for the treatment of obesity and Metabolic Dysfunction-Associated Steatohepatitis that is to be administered once weekly subcutaneously. DA-1726 acts as a dual agonist of GLP-1 receptors and glucagon receptors, leading to weight loss through reduced appetite and increased energy expenditure. DA-1726 has a well understood mechanism and, in pre-clinical mice models, resulted in improved weight loss compared to semaglutide.

MetaVia provided an update on its ongoing collaboration with Syntekabio an AI-driven drug discovery company, leveraging their proprietary DeepMatcher platform. Using AI-based compound-protein interaction modeling, Syntekabio has identified key disease targets for MetaVia's oral G-protein-coupled receptor 119, or GPR119, agonist, vanoglipel, or DA-1241. The analysis highlighted inflammatory diseases, cardiometabolic disorders, and cancer as the top predicted target areas, directly aligning with MetaVia's therapeutic focus. Notably, cancer was identified, in part, due to the strong reduction in inflammation observed in AI-predicted target pathways. "The AI modeling results provide strong confirmation that vanoglipel engages key inflammatory targets, which supports our strategy in metabolic dysfunction-associated steatohepatitis and potential type 2 diabetes," stated Hyung Heon Kim, President and CEO of MetaVia. "Furthermore, the identification of inflammation, cardiometabolic, and cancer-related pathways reinforces that we are focused in the right therapeutic areas. MetaVia continues to advance DA-1241 for MASH and T2D, bolstered by our Phase 2a clinical study results which demonstrated direct hepatic activity, improvements in glucose metabolism, and a favorable safety and tolerability profile in 109 patients over 16 weeks. Together, these insights give us confidence in DA-1241's broader therapeutic potential."

MetaVia Inc trading halted, volatility trading pause